# Efficacy & Safety of KAPVAY™ Extended-Release in Children & Adolescents With Attention Deficit Hyperactivity Disorder

> **NCT01439126** · PHASE4 · COMPLETED · sponsor: **Concordia Pharmaceuticals Inc., Barbados** · enrollment: 135 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** clonidine hydrochloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01439126
- **Lead sponsor:** Concordia Pharmaceuticals Inc., Barbados
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2014-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01439126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01439126, "Efficacy & Safety of KAPVAY™ Extended-Release in Children & Adolescents With Attention Deficit Hyperactivity Disorder". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01439126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*